{"entity":{"id":"parsaclisib","kind":"drug","name":"Parsaclisib","aka":["INCB050465"],"tldr":"Parsaclisib is an oral pi3k inhibitor from Incyte Corporation, in registered phase 2 trials for diffuse large B-cell lymphoma.","summary":"Parsaclisib is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by Incyte Corporation and Incyte Biosciences Japan GK, in diffuse large B-cell lymphoma. A phosphoinositide 3-kinase inhibitor: the name stem -lisib marks a small molecule that blocks PI3K signalling. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.","status":"phase-2","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov: trials of Parsaclisib","url":"https://clinicaltrials.gov/search?intr=Parsaclisib"}],"tags":["pipeline","ctgov-ingest","registry-only"],"related":[],"cancers":["dlbcl"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["incyte"],"institutions":[],"pathways":[],"terms":[],"trials":["nct04661007"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2, registry-only)","editedOn":"2026-09-16"},"modality":"Oral PI3K inhibitor","mechanism":"A phosphoinositide 3-kinase inhibitor: the name stem -lisib marks a small molecule that blocks PI3K signalling.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/parsaclisib/","neighbours":{"cancer":[{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"}],"company":[{"id":"incyte","kind":"company","name":"Incyte","route":"/companies/incyte/"}],"trial":[{"id":"nct04509700","kind":"trial","name":"Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)","route":"/trials/nct04509700/"},{"id":"nct04661007","kind":"trial","name":"To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL","route":"/trials/nct04661007/"}]}}